drugset / Trial / NCT04296461
Study of Welgenaleucel (UWC19) in Patients With Relapsed or Refractory B-cell Lymphoma
NaSingle-groupOpen-labelTreatment
Summary
This is an open-label, single-center Phase 1/2 study with a dose-escalation phase (Part 1) and a cohort expansion phase (Part 2) in patients with relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL).
Timeline
- Start
- 2020-07-27
- Primary completion
- 2021-06-30
- Completion
- 2021-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Welgenaleucel | Cell therapy | 4e+06 cells/kg | Intravenous |
| Subject | Welgenaleucel | Cell therapy | 8e+06 cells/kg | Intravenous |
| Subject | Welgenaleucel | Cell therapy | 1.2e+07 cells/kg | Intravenous |
| Subject | Welgenaleucel | Cell therapy | 1.6e+07 cells/kg | Intravenous |
| Subject | Welgenaleucel | Cell therapy | 2e+07 cells/kg | Intravenous |